Board of Directors rezadmin
Board of Directors
Challenging Us To Exceed Our Goals
André de Bruin
Mr. de Bruin joined the NxThera board of directors in 2009 with more than 35 years of global healthcare industry experience spanning the bio-pharmaceutical, medical device and in-vitro diagnostics markets. Prior to his retirement in 2004 as executive chairman of Quidel Corporation’s board of directors, André served as the company’s chief executive officer from 1998 until 2001. He was chairman, president and chief executive officer of Somatogen, a bio-pharmaceuticals company, prior to its acquisition by Baxter. Before joining Somatogen, André was chairman, president and chief executive officer of Boehringer Mannheim Corporation, a global healthcare company subsequently acquired by Hoffman-La Roche. Past experience includes advisory services for Ferrer, Freeman and Company LLC and various boards of directors. Most recently André was a board member of Nanosphere Inc., a public company in Northbrook, IL, engaged in the field of developing and commercializing molecular diagnostics for nucleic acid detection of infectious diseases. André received a B.S. in finance, economics and business from the University of Potchefstroom in South Africa.
Founder & Managing Director, Arboretum Ventures
Jan Garfinkle founded Arboretum Ventures in 2002 and is a Managing Director. At Arboretum, Jan focuses on promising medical technologies that enable meaningful healthcare system savings. Jan has led more than a dozen investments and currently serves as a board director for NxThera, Cereve, NeuMoDx, and Cardiac Dimensions. Jan’s past investments include HandyLab (acquired by Becton Dickinson in 2009 for $275 million), Esperion (IPO in 2013), and CardioMEMS (acquired by St. Jude Medical in 2014 for $435 million). Prior to founding Arboretum, Jan spent 20 years in entrepreneurial healthcare companies. She was President of Strategic Marketing Consultants, advising healthcare start-ups and major medical device companies. Prior to this, Jan held key management roles for two successful medical device start-ups, Advanced Cardiovascular Systems and Devices for Vascular Intervention. Each of these companies was acquired by Eli Lilly for more than $100 million and became the foundation for Guidant Corporation. Earlier in her career, Jan was an engineer and product manager for Procter & Gamble. Jan is the past President of the Michigan Venture Capital Association, a member of the Board of Directors for the National Venture Capital Association, and a member of the Healthcare Advisory Board at the University of Michigan. Jan earned a B.S. in Bioengineering from the University of California at Berkeley and an M.B.A. from the Wharton School at the University of Pennsylvania.
With over twenty years of operating and investing experience, Sami is currently a partner at AppleTree Partners leading the firm’s investments in a broad range of interests including therapeutic devices, sensors and healthcare IT solutions. Sami joined NxThera’s board of directors in 2008 as part of Aberdare’s Series A investment and is currently an independent director. Sami led investment in and served on the boards of several portfolio companies including Ablation Frontiers, VytronUS, Evalve, CaridoMEMs, Spiration, Cardica, CardioNet, CryoVascular and Nevro. Prior to joining Aberdare in 2006, Sami was vice president and head of the Compass Group at Guidant Corporation. In his role at Compass, Sami was responsible for Guidant’s corporate venture investments and merger & acquisition activities. In addition, Sami led Guidant’s west coast business development unit which included business development groups from the Vascular Intervention, Cardiac Surgery and Endovascular Solutions divisions. Sami also played founding roles in the launch and development of significant businesses for Guidant including coronary stents, carotid and peripheral systems. Sami began his career in medical devices at Advanced Cardiovascular Systems. He received a B.S. in Engineering from the American University of Beirut, an M.S. in Engineering from the University of Michigan, and an M.B.A. from the Stanford Graduate School of Business.
Co-Founder & Chief Technology Officer, NxThera, Inc.
Michael co-founded NxThera in 2008 to develop and commercialize the urology applications of the vapor platform technology that he invented. Michael has been a director and chief technology officer since NxThera’s inception. Prior to becoming an entrepreneur, Michael taught in several departments and performed research at the University of Minnesota, including the Department of Physiology, the Department of Urologic Surgery in the School of Medicine, the Institute of Technology, and the Carlson School of Management. Professor Hoey also taught in the department of Biological Sciences at Hamline University in St. Paul, Minnesota. Michael is an expert in the interaction of thermotherapy and tissue and a prolific inventor, with 72 patents granted and 94 patents pending, the majority of which are in the medical device field. Michael’s inventions include platform technologies, which are the foundation for products being sold, or in development for a variety of cardiac surgery, oncology, orthopaedics, pulmonology, general surgery, urology, gynecology, and vascular surgery applications. Michael has been a consultant to, as well as a founder/principal of, several medical products companies, which combined have raised over $250 million of capital.
President & Chief Executive Officer, NxThera, Inc.
Bob joined NxThera as its president and chief executive officer and a director in 2009 and has more than 20 years of experience in the medical device industry. Prior to joining NxThera, Bob was president, chief executive officer and a director of Restore Medical from 2005 until the company’s acquisition by Medtronic in July of 2008. Previous to Restore, Bob was the chief financial officer and vice president of global marketing for Endocardial Solutions, which was acquired by St. Jude Medical in 2005. Previously, Bob was the senior vice president and general manager of the auditory business for Advanced Bionics, and held several senior management positions with Medtronic, including vice president and general manager of the Surgical Navigation Technologies business unit, vice president of Corporate Strategy, and director of Corporate Development. Bob held senior positions in marketing, corporate development, legal and finance at General Mills, and practiced corporate, M&A and securities law with the Minneapolis law firm of Lindquist & Vennum. Bob currently serves as a director of Veran Medical, and has been a director of several privately-held and public medical devices companies. Bob received a J.D. from the Vanderbilt University School of Law, an M.B.A. from the University of St. Thomas, and a B.A. in accounting, economics & political science from Luther College.
Sigrid Van Bladel, PhD
Venture Partner, Aberdare Ventures
Sigrid Van Bladel, Ph.D. is a partner at Aberdare Ventures and joined NxThera’s board of directors in 2014. Sigrid previously was a Partner at New Enterprise Associates (NEA), a leading venture capital firm focusing on technology and healthcare start-ups, where she spent 18 years investing in biopharmaceutical and medical device companies. During her investing career, Sigrid has a long, well established record of backing early-stage healthcare technology enterprises. Successful exits where she was an investor and Board member include Myogen (formerly NASDAQ: MYOG, acquired by Gilead); Kai Pharma (an Aberdare investment acquired by Amgen); Novacept (acquired by Cytyc/Hologic); SurgRx (acquired by Johnson and Johnson); Xcel Pharmaceuticals (acquired by Valeant Pharma); Appriva Medical (acquired by EV3/Covidien); and Spiration Inc. (acquired by Olympus Medical Systems). For two years in a row during her tenure at NEA, Sigrid was included on Forbes Magazine’s Annual Midas List of the top 100 leading technology money makers, as only one of five women included on the list. Prior to joining NEA, Sigrid worked as a Management Consultant at McKinsey and Company. She holds a Master in Chemistry/Biotechnology (summa cum laude) and a Ph.D. (summa cum laude) in Molecular Biology from The University of Ghent, Belgium, and an M.B.A. from the Stanford Graduate School of Business.